Panorama, the #1 NIPT used in more than 3 million pregnancies.

It is the most reliable way of non-invasively assessing a baby’s health from a single blood draw from the mother

Results

Personalized results

Panorama offers a personalized risk score, which indicates whether your baby is at high or low risk for genetic disease. Your report could state the following:

Low Risk

A low risk result indicates that it is very unlikely that your baby is affected by one of the conditions on the Panorama panel.

High Risk

Panorama is a screening test, which means that this test does not make a final diagnosis. A high-risk result means that your pregnancy could at risk for a specific genetic condition. However, you cannot know for sure if your baby has that condition based on screening results alone. All medical decisions should be made after discussion with your clinician regarding diagnostic testing during the pregnancy, like amniocentesis or chorionic villus sampling (CVS), or testing the baby after birth.

Speak with your clinician to determine next steps, such as genetic counseling, detailed ultrasound, and the option of diagnostic testing.

No Result

In a small percentage of cases, Panorama may not be able to obtain suffcient information from your blood sample to determine an accurate result. If this occurs, a second blood sample may be requested.

Accurate test

Among commercially available NIPTs, Panorama has the highest published accuracy in determining the sex of the baby.

Reporting sex of the baby

Among commercially available NIPTs, Panorama has the highest published accuracy in determining the sex of the baby. Panorama’s ability to analyze SNPs unique to the Y chromosome and to detect the presence of vanishing twin pregnancies helps to overcome causes of inaccurate reporting of fetal sex common with other technologies.

If the mother is a known carrier of a genetic condition, or if there is a known family history of an x-linked condition, (for example, Duchenne Muscular Dystrophy) determination of the baby’s sex by NIPT can help determine the need for further diagnostic testing in the pregnancy.

Twin pregnancies

Clinically validated differentiation for twin pregnancies

Zygosity detection10

Recognized by the International Society for Prenatal Diagnosis (ISPD) as an important element in evaluating NIPT results for twins12

Individual fetal fraction for dizygotic twins10, 13

​An important metric necessary to interpret the reliability of NIPT results, ACOG recognizes that, without this measurement, aneuploidy could go undetected if the affected twin has low fetal fraction8

Individual fetal sex10

With zero fetal sex errors in published validation studies for both singletons and twins, patients and clinicians can have confidence in Panorama results5-7, 10

Other conditions screened9

  • Trisomy 21
  • Trisomy 18
  • Trisomy 13
  • Sex chromosome trisomies (reported when seen)*
  • 22q11.2 deletion syndrome (optional)*

*Identical twins only

PanoramaTM packages and prices

PanoramaTM Plus

189 000 FT
Down syndrome
Edwards syndrome
Patau syndrome
Turner syndrome
Klinefelter Syndrome
Jacob's Syndrome
Triple X syndrome
Gender
Triploidy
Vanishing twin
Maternal mosaicism
DiGeorge syndrome  (22q11.2 deletion syndrome)
1p36 deletion syndrome
Angelman syndrome
Prader-Willi syndrome
Cri-du-chat syndrome

PanoramaTM 22q

199 000 FT
Down syndrome
Edwards syndrome
Patau syndrome
Turner syndrome
Klinefelter Syndrome
Jacob's Syndrome
Triple X syndrome
Gender
Triploidy
Vanishing twin
Maternal mosaicism
DiGeorge syndrome  (22q11.2 deletion syndrome)
1p36 deletion syndrome
Angelman syndrome
Prader-Willi syndrome
Cri-du-chat syndrome

PanoramaTM Extra

239 000 FT
Down syndrome
Edwards syndrome
Patau syndrome
Turner syndrome
Klinefelter Syndrome
Jacob's Syndrome
Triple X syndrome
Gender
Triploidy
Vanishing twin
Maternal mosaicism
DiGeorge syndrome  (22q11.2 deletion syndrome)
1p36 deletion syndrome
Angelman syndrome
Prader-Willi syndrome
Cri-du-chat syndrome

Contact us!

Is PanoramaTM right for you?

We're here to help you find out!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2022 Natera, Inc. All Rights Reserved.